Basal-like carcinoma of the breast - The actual review and clinico-pathological corelations;Basal-like karcinom prsu - Aktuální přehled problematiky a klinicko-patologické korelace

Ceska Gynekologie

Volumn 72, Issue 5, 2007, Pages 351-354

  Kinkor, Zdeněk ^a,b  

^a Bioptická Laboratoř Sro ^*  (Czech Republic)

^b BIOPTICAL LABORATORY   (Czech Republic)

Author keywords

Basal like carcinoma; Breast; EGFR; Target therapy; Triple negative tumors

Indexed keywords

BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PAGET NIPPLE DISEASE; PATHOLOGY; REVIEW;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY;

EID: 36348997561     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Banerjee, S., Reis-Filho, JS., Ashley, S., et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 2006, 59, p. 729-735.
2. Bhargava, R., Gerald, WL., Li, AR., et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and Her-2 status and absence of EGFR-activating mutations. Mod Pathol, 2005, 18, p. 1027-1033.
3. Dabbs, DJ., Chivukula, M., Carter, G., et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistological profile. Modern Pathol, 2006, 19, p. 1506-1511.
4. Fulford, LG., Easton, DF., Reis-Filho, JS., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathol, 2006, 49, p. 22-34.
5. Hicks, DG., Short, SM., Prescott, NL., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6 and overexpress HER2 or EGFR. Am J Surg Pathol, 2006, 30, p. 1097-1104.
6. Kim, MJ., Ro, JY., Ahn, SH., et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotype. Hum Pathol, 2006, 37, p. 1217-1226.
7. Laakso, M., Loman, N., Borg, A., et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol, 2005, 18, p. 1321-1328.
8. Livasy, CA., Karaca, G., Nanda, R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 2006, 19, p. 264-271.
9. Livasy, CA., Perou, CM., Karaca, G., et al. Identification of basal-like subtype of breast ductal carcinoma in situ. Hum Pathol, 2007, 38, p. 197-204.
10. Marshall, J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer, 2006, 107, p. 1217-1218.
11. Rakha, EA., El-Sayed, ME., Green, AR., et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on cytokeratin expression. Histopathol, 2007, 50, p. 434-438.
12. Ribeiro-Silva, A., Ramalho, LNZ., Garcia, SB., et. al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of basal phenotype of breast cancer. Histopathol, 2005, 47, p. 458-466.
13. Siziopikou, KP., Ariga, R., Proussaloglou, KE., et al. The challenging estrogen receptor -negative/progesterone receptor-negative/Her-2- negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J, 2006, 12, p. 360-362.